









Markets
/
Stocks
/
nasdaq-coepw
/

Coeptis Therapeutics Holdings Inc

COEPW

View Detailed Chart

0.029USD

-0.001-2.39%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



Coeptis Therapeutics Holdings Inc

0.029

-0.001-2.39%

Overview Company Financials

Financials

Intraday

30m

Today

-2.39%

5 Days

+35.55%

1 Month

+68.24%

6 Months

-26.67%

Year to Date

+30.59%

1 Year

+Infinity%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(4)

Buy(5)

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Neutral

RSI(14)

50.400

Neutral

STOCH(KDJ)(9,3,3)

41.115

Neutral

ATR(14)

0.013

Low Volatility

CCI(14)

-51.852

Neutral

Williams %R

56.187

Sell

TRIX(12,20)

1.433

Buy

StochRSI(14)

17.719

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.030

Sell

MA10

0.032

Sell

MA20

0.028

Buy

MA50

0.026

Buy

MA100

0.021

Buy

MA200

0.023

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Ticker SymbolCOEPW

CompanyCoeptis Therapeutics Holdings Inc

CEO

Websitehttps://coeptistx.com/